Farmacoterapéutica de la anticoagulación: Revisión de la literatura

• Autores: Andres Felipe Posada Lopez, Julio César García C., Tatiana Pacheco P., Sara Arias V.
• Localización: Revista Colombiana de Enfermería, ISSN-e 1909-1621, Vol. 14, Nº. 1, 2017, págs. 65-81
• Idioma: español
• DOI: 10.18270/rce.v14i.2029
• Enlaces
  • Texto completo (pdf)
• Referencias bibliográficas
  • Kahn SR, Morrison DR, Cohen JM, Emed J, Tagalakis
  • V, Roussin A, et ál. Interventions for implementation
  • of thromboprophylaxis in hospitalized medical and
  • surgical patients at risk for venous thromboembolism.
  • Cochrane Database Syst Rev. 2013 jul.;7: 1-178.
  • Dennis RJ, Roa JH, Villadiego J, Méndez F, Vieda E,
  • Restrepo H. Venous thromboembolism prophylaxis
  • in Colombian surgical and medical patients: results
  • for Colombia of the Endorse study. Biomédica. 2011
  • jun.;31(2):200-8.
  • Vardi M, Haran M. A risk assessment model for the identification
  • of hospitalized medical patients at risk for
  • venous thromboembolism: the Padua Prediction Score:
  • a rebuttal. J Thromb Haemost. 2011 jul.;9(7):1437-8.
  • Evidence-Based Medicine Working Group. Evidencebased
  • medicine. A new approach to teaching the
  • practice of medicine. JAMA. 1992;268:2420-5.
  • Barbar S, Noventa F, Rosseto V, Ferrari A, Brandolin B,
  • Pertali M et ál. A risk assessment model for the identification
  • of hospitalized medical patients at risk for
  • venous thromboembolism: the Padua Prediction Score.
  • J Thromb Haemost. 2010;8: 2450-7.
  • Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell
  • DA Jr, Caprini JA. A validation study of a retrospective
  • venous thromboembolism risk scoring method. Ann
  • Surg. 2010 febr.;251(2):344-50.
  • Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification
  • of surgical and nonsurgical patients for venous
  • thromboembolic disease. Semin Hematol. 2001;38:12-9.
  • Green-top guideline n.o 37: reducing the risk of
  • thrombosis and embolism during pregnancy and the
  • puerperium. Londres: RCOG; 2009.
  • Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence
  • and risk patterns of venous thromboembolism in pregnancy
  • and puerperium – a register-based case-control
  • study. American Journal of Obstetrics and Gynecology.
  • ;198:233e1-7e.
  • Blondon M. Thromboprophylaxis after cesarean
  • section: decision analysis. Thrombosis Research.
  • ;127(Supl. 3):S9-12.
  • Kearon C, Aki E, Ornelas J, Blaivas A, Jimenez D, Bounameaux
  • H et ál. Antithrombotic Therapy for VTE Disease
  • CHEST Guideline and Expert Panel Report. CHEST.
  • ;149(2):315-52.
  • Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus
  • JI, Balaban EP et ál. Venous thromboembolism
  • prophylaxis and treatment in patients with cancer:
  • American Society of Clinical Oncology clinical practice
  • guideline update. J Clin Oncol. 2013;31:2189-204.
  • Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY,
  • Arcelus JI et al. Venous thromboembolism prophylaxis
  • and treatment in patients with cancer: American
  • Society of Clinical Oncology clinical practice guideline
  • update 2014. J Clin Oncol. 2015 en. 2; 33: 654-656.
  • Zachary Y, Roberts C. Thromboprophylaxis after
  • multiple trauma: What treatment and for how long?
  • International Journal of the Care of the Injured. 2009.
  • S3: S90-S94.
  • Decousus H, Tapson VF, Bergmann JF, Chong BH,
  • Froehlich JB, Kakkar AJ et ál. Factors at admission
  • associated with bleeding risk in medical patients:
  • findings from the improve investigators. Chest. 2011
  • en.;139(1):69-79.
  • Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus
  • H, Pini M, Chong BH et ál. Predictive and associative
  • models to identify hospitalized medical patients at risk
  • for venous thromboembolism. Chest. 2011; 140: 706-714.
  • January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE,
  • Cleveland JC Jr et ál. 2014 AHA/ACC/HRS guideline for
  • the management of patients with atrial fibrillation:
  • executive summary: a report of the American College
  • of Cardiology/American Heart Association Task Force
  • on practice guidelines and the Heart Rhythm Society.
  • Circulation. 2014 dic. 2;130(23):2071-104.
  • Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining
  • clinical risk stratification for predicting stroke and
  • thromboembolism in atrial fibrillation using a novel risk
  • factor-based approach: The Euro Heart Survey on Atrial
  • Fibrillation. Chest. 2010 febr.;137(2):263-72.
  • Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic
  • management of patients with prosthetic heart
  • valves: current evidence and future trends. Lancet.
  • ag.15;374(9689):565-76.
  • Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten
  • FW, Dempfle CE. Prothrombin complex concentrate
  • (Octaplex) in patients requiring immediate reversal of
  • oral anticoagulation. Thromb Haemost. 2007;98:790-7.
  • You JJ, Singer DE, Howard PA, Lane DA, Eckman MH,
  • Fang MC et ál. Evidence-based clinical practice guidelines
  • ed: American College of Chest Physicians Therapy
  • and Prevention of Thrombosis, 9th Oral Anticoagulant
  • Therapy: Antithrombotic. Chest. 2012;141:e44S-e88S.
  • Budnitz DS, Lovegrove MC, Shehab N, Richards CL.
  • Emergency hospitalizations for adverse drug events in
  • older Americans. N Engl J Med. 2011;365:2002-12.
  • Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl
  • CM, Brubacher JR et ál. Incidence, severity and
  • preventability of medication-related visits to the
  • emergency department: a prospective study. CMAJ.
  • ;178(12):1563-9.
  • Hill CE, Duncan A. Overview of pharmacogenetics in
  • anticoagulation therapy. Clin Lab Med. 2008;28:513-24.
  • Butchart EG. Antithrombotic management in patients
  • with prosthetic valves: a comparison of American and
  • European guidelines. Heart. 2009;95:430-6.
  • Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette
  • FA. Practice management guidelines for the prevention
  • of venous thromboembolism in trauma patients:
  • EAST practice management guidelines work group. J
  • Trauma. 2002 jul.;53(1):142-64.
  • Latronico N, Berardino M. Thromboembolic prophylaxis
  • in head trauma and multiple-trauma patients. Minerva
  • Anestesiol. 2008 oct.;74(10):543-8.
  • Douketis JD. Perioperative anticoagulation management
  • in patients who are receiving oral anticoagulant
  • therapy: a practical guide for clinicians. Thrombosis
  • Research. 2002;108(1):3-13.
  • Holbrook A, Schulman S, Witt DM, Vandvik PO, Lane
  • DA, Eckman MH et ál. Evidence-based management
  • of anticoagulant therapy: antithrombotic therapy and
  • prevention of thrombosis, 9th ed: American College
  • of Chest Physicians Evidence-Based Clinical Practice
  • Guidelines. Chest 2012;141 Issue 2, Supplement: e152Se184S.
  • García JC. Sobreanticoagulación. Medicina interna en
  • urgencias. 2.a ed. Bogotá: Celsus; 2013.
  • Riess H, Meier-Hellmann A, Motsch J, Elias M, Kursten
  • FW, Dempfle CE. Prothrombin complex concentrate
  • (Octaplex) in patients requiring immediate reversal of
  • oral anticoagulation. Thromb Haemost. 2007;98:790-7.
  • Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics
  • and pharmacokinetics of oral direct
  • thrombin and factor Xa inhibitors development. Clin
  • Pharmacokinet. 2009;48:1-22.
  • Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg
  • M. Meta-analysis of efficacy and safety of new oral
  • anticoagulants (dabigatran, rivaroxaban, apixaban)
  • versus warfarin in patients with atrial fibrillation. The
  • American Journal of Cardiology. 2012;110(3), 453-60.
  • Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata
  • DM, Chaturvedi S et ál. Guidelines for the primary
  • prevention of stroke: a statement for healthcare professionals
  • from the American Heart Association/American
  • Stroke Association. Stroke. 2014 dic.;45(12):3754-832.
  • Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and
  • safety of anticoagulant treatment in acute cardioembolic
  • stroke: a meta-analysis of randomized controlled
  • trials. Stroke. 2007 febr.;38(2):423-30.
  • Kashuk JL, Moore EE, Johnson JL, Biffl WL, Burlew CC,
  • Barnett C et ál. Progressive postinjury thrombocytosis
  • is associated with thromboembolic complications.
  • Surgery. 2010 oct.;148(4):667-74.
  • Wang AY, Ivany JN, Perkovic V, Gallagher MP, Jardine
  • MJ. Anticoagulant therapies for the prevention of intravascular
  • catheters malfunction in patients undergoing
  • haemodialysis: systematic review and meta-analysis of
  • randomized, controlled trials. Nephol Dial Transplant.
  • ;28:2875-88.
  • Patel JP, Roberts LN, Arya R. Anticoagulating obese
  • patients in the modern era. Br J Haematol. 2011
  • oct.;155(2):137-49.
  • Kornblith LZ, Howard B, Kunitake R, Redick B, Nelson
  • M, Cohen MJ, Callcut R. Obesity and clotting: body
  • mass index independently contributes to hypercoagulability
  • after injury. J Trauma Acute Care Surg. 2015
  • en.;78(1):30-8.
  • Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson
  • NL. Warfarin dosing and body mass index. Ann Pharmacother.
  • my.;48(5):584-8.
  • Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison
  • L, Alabdan NA et ál. Comparison of initial warfarin
  • response in obese patients versus non-obese patients.
  • J Thromb Thrombolysis. 2013 jul.;36(1):96-101.
  • Hoffmann P, Keller F. Increased major bleeding risk in
  • patients with kidney dysfunction receiving enoxaparin:
  • a meta-analysis. Eur J Clin Pharmacol. 2012;68: 757-65.
  • Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS,
  • Gage BF. Efficacy and safety of high-dose thromboprophylaxis
  • in morbidly obese inpatients. Thromb
  • Haemost. 2014 en.;111(1):88-93.
  • Willett KC, Alsharhan M, Durand C, Cooper MR.
  • Dosing of enoxaparin for venous thromboembolism
  • prophylaxis in obese patients. Ann Pharmacother.
  • dic.;47(12):1717-20.
  • Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Lowmolecular-
  • weight heparins in renal impairment and
  • obesity: available evidence and clinical practice recommendations
  • across medical and surgical settings. Ann
  • Pharmacother. 2009jun.;43(6):1064-83.
  • Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous
  • enoxaparin for therapeutic anticoagulation in hemodialysis
  • patients. Thrombosis Research. 2014;133:1023-8.
  • Lim W, Cook DJ, Crowther MA. Safety and efficacy of
  • low molecular weight heparins for hemodialysis in
  • patients with end-stage renal failure: a meta-analysis of
  • randomized trials. J Am Soc Nephrol. 2004;15:3192-206.
  • Schmid P, Brodmann D, Odermatt Y, Fischer AG,
  • Wuillemin WA. Study of bioaccumulation of dalteparin
  • at a therapeutic dose in patients with renal insufficiency.
  • J Thromb Haemost. 2009;7(10):1629.
  • Samama MM. Use of low-molecular-weight heparins
  • and new anticoagulants in elderly patients with renal
  • impairment. Drugs Aging. 2011 mzo. 1;28(3):177-93.
  • Schmid P, Fischer AG, Wuillemin WA. Low molecular
  • weight heparin in patients with renal insufficiency.
  • Swiss Med Wkly. 2009;139:438-52.
  • Bauersachs RM. Use of anticoagulants in elderly
  • patients. Thromb Res. 2012febr.;129(2):107-15.
  • Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants
  • in elderly patients: practical recommendations.
  • Clin Interv Aging. 2009;4:165-77.
  • Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral
  • anticoagulants in elderly adults: evidence from a
  • meta-analysis of randomized trials. J Am Geriatr Soc.
  • my.;62(5):857-64.
  • Hill J, Treasure T. Reducing the risk of venous thromboembolism
  • in patients admitted to hospital: summary
  • of NICE guidance. British Medical Journal. 2010; 340:c95.
  • Siguret V, Gouin-Thibault I, Gaussem P, Pautas E.
  • Optimizing the use of anticoagulants (heparins and
  • oral anticoagulants) in the elderly. Drugs Aging.
  • sept.;30(9):687-99.
  • Knight M; UKOSS. Antenatal pulmonary embolism:
  • risk factors, management and outcomes. BJOG. 2008
  • mzo.;115(4):453-61.
  • Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda
  • P, Negrier C et ál. A risk score for the management of
  • pregnant women with increased risk of venous thromboembolism:
  • a multicentre prospective study. British
  • Journal of Haematology. 2009;145:825-35.
  • Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A,
  • Pengo V et ál. Risk of recurrence after a first episode of
  • symptomatic venous thromboembolism provoked by
  • a transient risk factor: a systematic review. Arch Intern
  • Med. 2010;170(19):1710-6.
  • Bendinelli C, Balogh Z. Postinjury thromboprophylaxis.
  • Curr Opin Crit Care. 2008dic.;14(6):673-8.
  • Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K. Bivalirudina
  • for prevention of venous thromboembolism in
  • high risk trauma patients: a pilot study. J Am Coll Surg.
  • nov.;209(5):589-94.
  • Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder
  • HC, Mejia VA. Unfractionated heparin three times
  • a day versus enoxaparin in the prevention of deep
  • vein thrombosis in trauma patients. Am Surg. 2010
  • jun.;76(6):563-70.
  • Khorana AA, Kuderer NM, Culakova E, Lyman GH,
  • Francis CW. Development and validation of a predictive
  • model for chemotherapy-associated thrombosis.
  • Blood. 2008 my. 15;111(10):4902-7.
  • Petralia GA, Kakkar AK. Treatment of venous thromboembolism
  • in cancer patients. Semin Thromb
  • Hemost. 2007 oct.;33(7):707-11.
  • Queensland Health. Guideline for anticoagulation and
  • prophylaxis using low molecular weight heparin. State
  • of Queensland. 2014. Document Number # QH-GDL-95.
  • Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, López-
  • Jiménez L, García-Bragado F, Quintavalla R et ál.
  • Bleeding complications associated with anticoagulant
  • therapy in patients with cancer. Thromb Res. 2010
  • abr.;125 Supl. 2:S58-61.